Research and Development Daily Today, a number of drugs were approved for listing by the Drug Administration.

2020.07.30 Research and Development NEWS: AbbVie Oral CGRP Receptor Antagonist Reaches Phase 3 Clinical Endpoint; Roche IL-6R Antibody New Crown Phase III Clinical Failure; Mercado Innovation Therapy Recognized by FDA Breakthrough Therapy; BMS Resysits CAR-T Cell Therapy Listing Application for Treatment of Multiple Myeloma... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, can read the original version) "Drug Development" Roche IL-6R antibody new crown phase III clinical failure Roche announced that its IL-6 receptain antibody Actemra in a phase III clinical called COVACTA failed to reach the trial grade 1 and the main secondary endpoint.
the trial recruited new coronary patients with severe pneumonia who needed hospitalization, comparing actemra with placebo's effect on patients' condition in the context of standard therapy, missing a level 7 gradient severity score.
AbbVie oral CGRP receptor antagonists reached Phase 3 clinical endpoint Today, AbbVie announced that it reached its primary endpoint in the Phase 3 clinical trial ADVANCE for the prevention of migraines, with an average reduction in the average number of migraine days per month compared to placebo during the 12-week treatment period.
(Drug Approval) Mercerton Innovation Therapy was approved by the FDA Breakthrough Therapy Today, Mercerton announced that the FDA has awarded its oxygen-deficoxide-inducing factor-2 alpha inhibitor MK-6482 breakthrough therapy for the treatment of patients with renal cell carcinoma associated with von Hippel-Lindau disease who carry non-metastatic RCC tumors smaller than 3 cm in size.
4 innovative drugs approved for listing in China on the 30th, according to the NMPA drug approval notice shows that four innovative drugs were approved for listing in China, respectively, the hepatitis C drug Lavidavi, the first acoustic stroke drug Idalavin right-handol, Mercadon sugar-lowering drug Aigley net and Pfizer eczema drug Clyboro.
Howson "Engli Net Tablet" was approved today, Howson Pharmaceuticals new category 4 generic drug "Engli Net Tablet" was approved by the State Drug Administration, becoming the first domestic imitation of the variety, at the same time as through consistency evaluation.
Beijing Fuyuan "Menglust sodium chewing tablets" approved 30, drug approval notice shows that Beijing Fuyuan Pharmaceuticals 4 generic drugs "Mengluste sodium chewing tablets" approved for listing, at the same time as through consistency evaluation, officially entered the third batch of collection.
BMS resubmitted its CAR-T cell therapy listing application for the treatment of multiple myeloma bMS and bluebird bio today jointly announced that it has submitted to the FDA a joint application for a license for the biological products of car-Tedcabtagene vicleucel, a joint development of the drug.
Oshitini assisted treatment of early EGFR mutation lung cancer was approved by the FDA breakthrough therapy 30, AstraZeneiny announced in the United States breakthrough therapy identified as an auxiliary treatment for early epidermis growth factor receptor mutation non-small cell lung cancer patients after a full excision of curative treatment.
treatment of breast cancer Novartra PI3K inhibitors approved by the European Union 29, Novarhua announced that the European Commission has approved Piqray and fluvys for use in post-menoping women and men with breast cancer patients.
These patients tested positive for hormone receptors (HR plus), human epiderm growth factor receptors-2 were negative (HER-), and the disease continued to progress after a single endocrine therapy, carrying THE3CA mutations and showing local late stage or metastasis. according to the latest information on the CDE website, the clinical application of
Regenerative City Class 1 innovative therapy was accepted, and the regenerative city submitted a clinical application for anti-HIV-1 chimed antigen receptor T-cell injection, which was accepted on July 30.
China Resources Seko, Yangzijiang "Viglitin tablets" approved today, drug approval notice shows that China Resources Saiko and Yangzijiang Pharmaceuticals 4 generic drugs "Viglietin tablets" were approved for listing, successfully entered the third batch of the board.
East China Medicine Anaquon tablets were approved on the 30th, East China Pharmaceuticals 4 generic anaqual tablets were approved for listing, as through consistency evaluation.
Xinhua Pharmaceutical Phenyhera tablets through generic consistency evaluation 30, Shandong Xinhua Pharmaceuticals issued a notice that received the State Drug Administration approved the issuance of benzodiazepine hydrochloric acid (25 mg) "drug supplement application approval notice", the product through generic drug quality and efficacy consistency evaluation.
company became the second company in China to pass a generic consistency evaluation of benzene hela postcards (25 mg).
.